Roivant Sciences Ltd.
HealthcareNASDAQ:ROIV · NASDAQ Global Market
+$0.57 today
Vol 5.27M · Avg 5.63M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$8.3M of revenue converted into -$299.8M of net income for the selected period. Gross margin is 84.5% and net margin is -4699.1%, showing how much revenue survives after costs and taxes. EPS is $-0.51, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.3M -71.6% | $29.1M -11.2% | $32.7M +3.8% | $31.5M -43.0% | $55.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.3M +41.1% | $911.0K -43.0% | $1.6M -47.3% | $3.0M -66.2% | $9.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $7.0M -75.2% | $28.1M -9.6% | $31.1M +9.2% | $28.5M -38.5% | $46.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 84.4% -12.4pp | 96.9% +1.8pp | 95.1% +4.7pp | 90.4% +6.6pp | 83.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $681.8M +23.9% | $550.4M +25.1% | $439.9M -3.1% | $454.1M -6.0% | $483.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $610.5M +3.2% | $591.4M +42.1% | $416.1M +8.5% | $383.4M -50.5% | $775.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.3B +13.2% | $1.1B +33.4% | $856.0M +2.2% | $837.5M -33.4% | $1.3B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.3M -76.2% | $14.1M -36.1% | $22.0M +16.9% | $18.9M +217.9% | $5.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$261.2M +60.9% | -$667.5M -114.4% | $4.6B +651.8% | -$838.2M +8.0% | -$910.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -3162.6% -865.0pp | -2297.6% -16434.7pp | 14137.1% +16795.4pp | -2658.3% -1010.9pp | -1647.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$1.3B -15.4% | -$1.1B -35.0% | -$824.9M -2.0% | -$809.0M +33.2% | -$1.2B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -15560.6% -11727.3pp | -3833.3% -1311.6pp | -2521.7% +44.1pp | -2565.9% -374.1pp | -2191.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $178.1M -31.1% | $258.4M +76.5% | $146.4M +355.0% | $32.2M +8622.0% | $369.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $34.8M +24.3% | $28.0M +297.2% | $7.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.0B +136.2% | $432.1M -92.0% | $5.4B +7198.0% | -$76.0M -126.4% | $288.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$264.6M +61.2% | -$681.6M -114.9% | $4.6B +616.1% | -$885.0M +4.2% | -$923.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -3203.1% -857.1pp | -2346.0% -16309.5pp | 13963.4% +16770.2pp | -2806.8% -1136.0pp | -1670.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $133.3M +176.8% | $48.2M +124.0% | $21.5M +426.8% | $4.1M +1006.2% | $369.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$299.8M -74.3% | -$172.0M -104.0% | $4.3B +531.0% | -$1.0B -19.4% | -$845.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | -3629.2% -3037.2pp | -592.0% -13886.1pp | 13294.2% +16494.4pp | -3200.2% -1671.3pp | -1528.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -79.2% | -$0 -104.3% | $6 +490.8% | -$1 -12.7% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -79.2% | -$0 -104.6% | $5 +468.3% | -$1 -12.7% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $693.9M -4.3% | $725.4M -7.4% | $783.2M +9.9% | $712.8M +6.4% | $669.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $693.9M -4.3% | $725.4M -12.7% | $831.0M +16.6% | $712.8M +6.4% | $669.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.72B
Royalty Pharma plc
NASDAQ:RPRX
$23.72B
Exact Sciences Corporation
EXAS
$20.03B
Moderna, Inc.
NASDAQ:MRNA
$20.03B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.64B
Ascendis Pharma A/S
NASDAQ:ASND
$13.67B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.17B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.17B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.82B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$210.23M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ROIV generate?
Roivant Sciences Ltd. (ROIV) reported $8.26M of revenue in fiscal 2025.
Is ROIV profitable?
Roivant Sciences Ltd. (ROIV) reported -$299,771,000.00 of net income, with a net margin of -3629.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.